News

Podcast

Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.

To listen, login to the website.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read more about the stories in this podcast:

Senate Votes 98-2 to Ban Pharmacist Gag Clauses

Launch of Highly Efficacious HIV, Tuberculosis, and Malaria Vaccines Unlikely, Study Says

When Employee Healthcare Costs Move Stocks

A Multidisciplinary Approach to Managing Complexities in Cancer Care

Related Videos
Bridgette J. Picou, LVN, ACLPN, The Well Project
1 expert in this video
Nini Wu, MD, Navista
1 expert in this video
1 expert in this video
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
1 expert in this video
1 expert in this video
Lalan Wilfong, MD
Related Content
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Young adult HIV | Image credit: ViDi Studio - stock.adobe.com
May 20th 2025

Adolescents, Young Adults With HIV at Increased Risk of Mental Health Issues

Julia Bonavitacola
Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
HIV | Image credit: RAJCREATIONZS - stock.adobe.com
May 15th 2025

Implementation of HIV Molecular Cluster Detection in US

Julia Bonavitacola
The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo